血浆置换与达雷妥尤单抗治疗骨髓瘤管型肾病
研究基于25个美国学术癌症中心数据,采用靶试验模拟方法分析新诊断轻链管型肾病患者早期接受血浆置换或达雷妥尤单抗与90天肾脏恢复的关联。结果显示两者均与90天肾脏恢复无显著关联,但亚组分析提示血浆置换可能对特定人群有益。
要点
- 早期血浆置换与90天肾脏恢复无显著关联(OR 1.48,95%CI 0.96-2.30)。
- 早期达雷妥尤单抗与90天肾脏恢复无显著关联(OR 1.46,95%CI 0.84-2.55)。
- 亚组分析提示血浆置换可能对新诊断骨髓瘤或AKI 3期患者更有益。
核心结论
- 在多中心队列研究中,早期血浆置换或达雷妥尤单抗均与90天肾脏恢复无显著关联。
研究设计与样本
- 基于25个美国学术癌症中心数据进行的靶试验模拟研究,纳入新诊断轻链管型肾病患者。
- 血浆置换靶试验纳入549例 eligible 患者,其中158例(28.8%)接受血浆置换。
- 达雷妥尤单抗靶试验纳入474例 eligible 患者,其中136例(28.7%)接受达雷妥尤单抗。
- 肾脏恢复定义为90天时存活、未接受肾脏替代治疗且AKI严重程度至少改善一个分期。
- 采用倾向评分重叠权重的逻辑回归调整混杂因素。
主要发现
- 血浆置换与90天肾脏恢复无显著关联(OR 1.48,95%CI 0.96-2.30)。
- 达雷妥尤单抗与90天肾脏恢复无显著关联(OR 1.46,95%CI 0.84-2.55)。
- 亚组分析中,血浆置换在新诊断骨髓瘤患者中与90天肾脏恢复的OR高于复发患者。
- 亚组分析中,血浆置换在LCCN诊断时AKI 3期患者中与90天肾脏恢复的OR高于AKI 1或2期患者。
临床怎么用
- 对于新诊断轻链管型肾病患者,早期血浆置换或达雷妥尤单抗不宜作为常规推荐用于促进肾脏恢复。
- 可考虑对特定亚组(如新诊断骨髓瘤或AKI 3期)个体化评估血浆置换的潜在获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma light chain cast nephropathy (LCCN) is often treated with plasma exchange (PLEX) or the anti-CD38 monoclonal antibody, daratumumab. However, rigorous studies supporting these therapies for LCCN are limited. Using data from 25 U.S.-based academic cancer centers, we conducted two target trials examining the association between early receipt of PLEX or early receipt of daratumumab and kidney recovery in patients with newly diagnosed LCCN. Kidney recovery was defined as being alive, not on kidney replacement therapy, and with an improvement of at least one stage of AKI severity, all assessed at 90 days. Secondary outcomes included kidney recovery at 60 and 180 days. Logistic regression with propensity score overlap weights was used to adjust for confounders. Of 549 eligible patients for the PLEX target trial, 158 (28.8%) received PLEX. There was no association between PLEX and kidney recovery at 90 days (OR 1.48, 95% CI: 0.96-2.30). However, in subgroup analyses, PLEX was associated with higher odds of kidney recovery at 90 days among patients with newly diagnosed multiple myeloma compared to those with relapsed disease, as well as higher odds of kidney recovery among those with Stage 3 versus Stage 1 or 2 AKI at the time of LCCN diagnosis. Of 474 patients eligible for the daratumumab target trial, 136 (28.7%) received daratumumab. Daratumumab was not associated with kidney recovery at 90 days (OR 1.46, 95% CI: 0.84-2.55). Thus, in this multicenter cohort study, neither PLEX nor daratumumab was associated with kidney recovery at 90 days.
引用
- Shincovich CI, Chewcharat A, Adomi M, et al. Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy. Am J Hematol. 2026. PMID: 42864738. doi:10.1002/ajh.70516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。